Preventing VTE in Cancer, Maintaining Low Bleeding Risk: Reduced-Dose Apixaban
Mario Balsa, medical oncology resident at Institut Català d’Oncologia, shared an insightful post on X:
” ‘New’ The New England Journal of Medicine (NEJM) study in 1,766 patients with cancer-associated VTE:
- Reduced-dose apixaban (2.5mg BID) vs full dose (5mg BID)
- VTE recurrence: 2.1% vs 2.8%
- Clinically relevant bleeding: 12.1% vs 15.6%
Same protection, less bleeding. Sometimes, less really is more!”
Effects of reduced dose of an oral anticoagulant on thromboembolic events and bleeding are discussed in the new study ”Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism” published by Isabelle Mahé et al. in the New England Journal of Medicine (NEJM).
In patients with active cancer and venous thromboembolism, extended treatment with reduced-dose apixaban was as effective as the full dose in preventing recurrent events.
Moreover, dose reduction resulted in fewer bleeding complications.
This supports reduced-dose apixaban as a safer alternative for long-term anticoagulation in this population.
Never miss the scientific advancements in the World of Hematology, read Hemostasis Today.
-
Jul 13, 2025, 15:33ISTH Now Accepting Applications for SSC Leadership Roles
-
Jul 13, 2025, 15:32Last Chance to Apply: EHA Preceptorship on Precision Hematology in Germany!
-
Jul 11, 2025, 19:14ISTH 2025 for Cardiac Surgery: LEX-211 (FARES-II) Trial Shows Promising Results
-
Jul 11, 2025, 16:48GPAS 2025: Shaping the Future of Bleeding Disorder Care
-
Jul 10, 2025, 11:23HTRS Thanks CSL Behring for Its Ongoing Commitment to Research Support
-
Jul 13, 2025, 18:182025 ASH ISTH NBDF WFH monitoring report Confirms Strength of 2021 VWD Diagnosis and Management Guidelines
-
Jul 13, 2025, 17:57Preventing VTE in Cancer, Maintaining Low Bleeding Risk: Reduced-Dose Apixaban
-
Jul 13, 2025, 17:172024 NHLBI Workshop Charts Promising Future Directions for ECMO-Induced Coagulopathy
-
Jul 13, 2025, 16:483-Factor Prediction Tool Targets Inactivity After Stroke to Prevent Recurrent Heart Events
-
Jul 12, 2025, 16:21Richard Buka։ Evolution’s Imprint on Blood, Natural Selection Shaping Today’s Hematologic Disorders
-
Jul 13, 2025, 16:05EMA and HMA Mark a Key Step with 1st AI Observatory Report
-
Jul 13, 2025, 15:35World’s First Liver Transplant for Plasminogen Deficiency Performed at KFSHRC
-
Jul 7, 2025, 17:08Detecting Anti-Drug Antibodies to Emicizumab: A French Center’s Remarkable Experience
-
Jul 6, 2025, 21:00From Untouchable to Editable: How 21st-Century Gene Editing Breakthroughs Clash with Systemic Barriers
-
Mar 6, 2025, 17:15Olympus Announces Launch of Single-Use Hemostasis Clip
-
Jul 10, 2025, 18:25Dr. Carol Kasper: Honoring the Legacy
-
Jul 8, 2025, 08:26ASH and HVO Collaborate to Expand Hematology Training in LMICs
-
Jul 6, 2025, 15:02Patients as Experts: EHC Calls for Early Involvement in HTA Systems
-
Jul 6, 2025, 14:56Missed ISTH 2025? Congress Daily Has You Covered
-
Jul 6, 2025, 11:48Japan's Youth Engagement in Hemophilia Care: Where Even the Doctors Get It – HABIT Summit 2025